Streamlining Anthem (Elevance Health) Beovu Prior Authorization

Efficiently manage Anthem (Elevance Health) Beovu prior authorization with Klivira's automation platform. Navigate complex payer requirements for this high-volume specialty drug with clarity and speed.

For revenue cycle directors and prior authorization coordinators, securing timely approvals for specialty drugs like Beovu is critical. Understanding Anthem's specific requirements, submission channels, and policy nuances is key to minimizing denials and accelerating patient access to essential anti-VEGF therapy.

Navigating Anthem's Prior Authorization Requirements for Beovu

Beovu (brolucizumab) is an anti-VEGF therapy for wet age-related macular degeneration (wet AMD), typically administered as an intravitreal injection. As a specialty injectable, its prior authorization (PA) with Anthem-licensed plans primarily falls under the medical benefit. This requires adherence to Anthem's specific clinical criteria, site-of-care policies, and documentation standards to ensure coverage for eligible members.

Key Channels for Beovu Prior Authorization Submission to Anthem

**Availity Essentials:** The primary multi-payer portal for initiating medical PAs, checking member benefits, and uploading supporting clinical documentation for Anthem commercial and Medicare Advantage plans.
**X12 278 Transactions:** For providers with integrated systems, electronic prior authorization requests for medical benefit drugs like Beovu can be submitted via X12 278 transactions through a clearinghouse.
**Direct Provider Portal:** For specific scenarios or lines of business, Anthem's state-specific provider portals, often accessed via Availity, may offer direct PA submission tools.

Beovu Medical Policy and Clinical Criteria from Anthem

Anthem operating companies publish medical policies and clinical utilization management guidelines that govern Beovu coverage. These state-specific policy libraries are typically accessible through provider portals linked via Availity. Criteria may be Anthem-developed or incorporate standards from vendors like MCG. Providers must reference the specific policy number, plan-state context, and effective date for accurate submission.

Electronic Prior Authorization (ePA) and Da Vinci Initiatives for Beovu

Elevance Health, the parent company of Anthem, actively participates in Da Vinci Project initiatives, exploring HL7 FHIR-based standards like Prior Authorization Support (PAS). For immediate electronic submission of medical benefit PAs like Beovu, X12 278 transactions remain a widely adopted standard. Klivira integrates with EMRs to automate the generation and submission of these electronic PAs, streamlining the process and reducing manual effort for high-volume specialty drugs.

Common Denial Reasons and Appeal Pathways for Beovu with Anthem

Denials for Beovu prior authorizations from Anthem can result from medical necessity criteria not being met, insufficient clinical documentation, or failure to complete prerequisite step therapy requirements. Site-of-service mismatches are also a frequent denial pattern for specialty injectables, given Anthem's active site-of-care policies. Appeals for medical benefit denials typically follow the Anthem operating-company appeals process, with peer-to-peer review options available.

Optimizing Turnaround Times for Beovu Prior Authorizations with Anthem

Prior authorization turnaround times for Beovu with Anthem vary by plan type and state. Medicare Advantage and Medicaid managed care plans are subject to CMS-0057-F, mandating 72-hour standard and 24-hour expedited decision timeframes. Commercial plan timeframes are governed by state insurance regulations. Klivira's automation platform helps accelerate turnaround by ensuring complete, accurate submissions and efficient tracking.

Frequently asked questions

Is Beovu considered a medical or pharmacy benefit drug by Anthem?

Beovu (brolucizumab) is typically covered under the medical benefit by Anthem-licensed plans, as it is an intravitreal injection administered in a clinical setting. Prior authorization requirements will follow medical benefit guidelines and submission channels.

What are the primary electronic submission channels for Beovu prior authorization with Anthem?

For medical benefit Beovu prior authorizations, the primary electronic channels are X12 278 transactions submitted through a clearinghouse or direct submission via the Availity Essentials portal, which interfaces with Anthem's systems.

Where can I access Anthem's medical policies and clinical criteria for Beovu?

Anthem's medical policies and clinical utilization management guidelines for Beovu are published on the respective state-licensed Anthem plan's provider website, often accessible via the Availity portal. Always verify the specific policy number and effective date.

What are common reasons for Beovu prior authorization denials from Anthem?

Common denial reasons include insufficient clinical documentation, failure to meet medical necessity criteria, incomplete step therapy requirements, or non-adherence to site-of-service policies for specialty injectables.

How does Klivira streamline Beovu prior authorizations with Anthem?

Klivira's platform integrates with your EMR to automate the data extraction, form population, and submission of Beovu prior authorizations to Anthem via X12 278 or portal. This reduces manual effort, improves accuracy, and provides real-time status tracking.